SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 15, 1997
VIMRx Pharmaceuticals Inc.
(Exact name of registrant as specified in charter)
Delaware 0-19153 06-1192468
(State or other juris- (Commission (IRS Employer
diction of incorp- File Number) Identification No.)
oration)
2751 Centerville Road, Wilmington, Delaware 19808
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (302) 998-1734
Not applicable
(Former name or former address, if changed since last report)
Item 4. Changes in Registrant's Certifying Accountant
For more than the two most recent fiscal years of the Company,
the independent auditors of the Company have been Richard A. Eisner &
Company, LLP, who have been dismissed upon recommendation of the Audit
Committee effective May 15, 1997. At no time did any report on the
financial statements of the Company by Richard A. Eisner & Company, LLP
contain an adverse opinion or a disclaimer of opinion, or a
qualification or modification as to uncertainty, audit scope or
accounting principles. The decision to change accountants was
occasioned by the developments of the past year, and not by any
disagreement or advice given on any matter of accounting principles or
practices, financial statement disclosure, or auditing scope or
procedure. In particular, in light of the acquisition by the Company of
a controlling interest in Innovir Laboratories, Inc. the Audit
Committee concluded that it would be most efficient and in the best
interests of both Innovir and the Company for the same auditors to
audit both companies. The Company solicited proposals from four
auditing firms, including Richard A. Eisner & Company, LLP. KPMG Peat
Marwick LLP was chosen as a result of this process, and was engaged by
the Company as its principal auditors on May 15, 1997.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
16. Letter of Richard A. Eisner & Co., LLP*
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
VIMRx PHARMACEUTICALS INC.
(Registrant)
By:/s/ L. William McIntosh
--------------------------
L. William McIntosh
Chief Financial Officer
Dated: May 21, 1997
<PAGE>
{LETTERHEAD OF RICHARD A. EISNER & CO., L.L.P.}
May 20, 1997
VIMRX Pharmaceuticals Inc.
2751 Centerville Road, Suite 210
Wilmington, Delaware 19808
Dear Sirs and Mesdames:
We have read the statements made by VIMRx Pharmaceuticals Inc. in
Item 4 of the accompanying Form 8-K which is being filed with the
Securities and Exchange Commission. We agree with the statements
concerning our Firm.
Very truly yours,
/s/ RICHARD A. EISNER & CO., L.L.P.
